Beam Therapeutics BEAM Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.
The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Beam Therapeutics's business combination contingent consideration arrangements change in amount of contingent consideration liability1.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Beam Therapeutics's business combination contingent consideration arrangements change in amount of contingent consideration liability1?
- Beam Therapeutics (BEAM) reported business combination contingent consideration arrangements change in amount of contingent consideration liability1 of -$514K in Q1 2026.
- How has Beam Therapeutics's business combination contingent consideration arrangements change in amount of contingent consideration liability1 changed year-over-year?
- Beam Therapeutics's business combination contingent consideration arrangements change in amount of contingent consideration liability1 decreased by 2003.7% year-over-year, from $27K to -$514K.
- What does business combination contingent consideration arrangements change in amount of contingent consideration liability1 mean?
- This metric tracks adjustments to the estimated liability for contingent consideration, often referred to as earn-outs, resulting from past business acquisitions. Changes in this value reflect updates to the probability or timing of achieving specific performance milestones post-merger. It provides insight into the accuracy of acquisition valuations and the ongoing financial obligations related to inorganic growth.